Related Experiment Video
Updated: Sep 11, 2025
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
The Role of [177Lu] Lu-Satoreotide Tetraxetan in Somatostatin Receptor-Positive Neuroendocrine Tumors
Kalyan Mansukhbhai Shekhda1, Shaunak Navalkissoor2
1Neuroendocrine Tumour Unit, Royal Free Hospital NHS Foundation Trust, ENETS Centre of Excellence, London, UK.
Abstract:
Peptide receptor radionuclide therapy (PRRT) targeting the somatostatin receptor with receptor agonists has emerged as a key treatment in the management of well-differentiated neuroendocrine tumors (NETs). The therapeutic efficacy of these agents has traditionally been attributed to receptor-mediated internalization of the radiolabeled peptide into tumor cells. In contrast, somatostatin receptor (SSTR) antagonists bind to the receptor without undergoing significant internalization. Despite this theoretical limitation, accumulating preclinical and clinical evidence supports the therapeutic utility of SSTR antagonists. These agents have been shown to bind to a greater number of receptor sites and exhibit prolonged tumor retention, properties that may enhance both imaging sensitivity and therapeutic efficacy. Among the antagonists studied, [¹⁷⁷Lu]Lu-satoreotide tetraxetan is the most extensively investigated to date. In this article, we review both preclinical and clinical data evaluating the efficacy and safety of [¹⁷⁷Lu]Lu-satoreotide tetraxetan in the treatment of neuroendocrine tumors. We also provide a brief overview of other SSTR antagonists currently under investigation.
Insights
Somatostatin receptor antagonists show promise for neuroendocrine tumor treatment, offering prolonged tumor retention and enhanced efficacy. [177Lu]Lu-satoreotide tetraxetan is a leading agent in this evolving therapeutic landscape.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceutical Therapy
Background:
- Peptide receptor radionuclide therapy (PRRT) using somatostatin receptor agonists is standard for well-differentiated neuroendocrine tumors (NETs).
- Therapeutic success is traditionally linked to receptor internalization, a process not typical for receptor antagonists.
Purpose of the Study:
- To review preclinical and clinical data on [177Lu]Lu-satoreotide tetraxetan for NET treatment.
- To evaluate the efficacy and safety of SSTR antagonists in NET management.
- To provide an overview of other SSTR antagonists in development.
Main Methods:
- Review of preclinical studies investigating SSTR antagonists.
- Analysis of clinical trial data for [177Lu]Lu-satoreotide tetraxetan.
- Literature search for ongoing SSTR antagonist research.
Main Results:
- SSTR antagonists demonstrate therapeutic utility despite limited internalization.
- [177Lu]Lu-satoreotide tetraxetan exhibits greater receptor binding and prolonged tumor retention.
- Evidence supports the efficacy and safety of [177Lu]Lu-satoreotide tetraxetan in NETs.
Conclusions:
- SSTR antagonists represent a viable therapeutic strategy for NETs.
- [177Lu]Lu-satoreotide tetraxetan is a promising agent with potential for improved imaging and therapy.
- Further investigation into SSTR antagonists is warranted.
More Related Videos
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
